Sign in Subscribe
Bulletin

Bulletin

Examine access policies and pathways for innovative medicines in China. We closely monitor the latest developments in these areas and provide concise updates, along with our take, delivered to your inbox every Wednesday.
Apr
02
China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback

China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback

As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
3 min read
Mar
05
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
5 min read
Feb
12
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines

NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines

The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
4 min read
Jul
10
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
4 min read
Jul
03
NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

Executive Summary In China, both public and private not-for-profit hospitals are required to adhere to the Medical Service Pricing Catalogs
5 min read
Jun
26
China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years

Executive Summary City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
4 min read
Jun
05
Accessing Innovative Orphan Therapies in China: Local Advancements

Accessing Innovative Orphan Therapies in China: Local Advancements

These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
3 min read
May
08
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
5 min read
Apr
24
China Local Pilots Expedite Access to Innovative Medicine

China Local Pilots Expedite Access to Innovative Medicine

These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
4 min read
Apr
03
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions

Key Direction for Huiminbao Drug Formulary at China's National Two Sessions

During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
2 min read